Product category:
Contract research
News Release from: Perkin Elmer LAS (UK)
Edited by the Laboratorytalk Editorial
Team on 18 April 2003
Collaboration to study Alzheimer's
disease
Programme focusses on identifying protein and gene targets involved in the onset and progression of Alzheimer's in order to enhance diagnostics and drug discovery
PerkinElmer has entered into a research collaboration on the proteomics of Alzheimer's disease with the Rush Alzheimer's Disease Center and the Buck Institute for Age Research The programme focuses on identifying protein and gene targets involved in the onset and progression of Alzheimer's disease in order to enhance diagnostics and drug discovery
This article was originally published on Laboratorytalk on 19 Apr 2002 at 8.00am (UK)
Related stories
Probing the source of diabetes
Newly developed gene probes increase efficiency and speed of research in studies of type 1 (juvenile) diabetes, detecting the presence of alleles by hybridisation reaction
Manage the entire gene expression process
With microarray labs generating more than one million primary data points daily, this gene expression data management software could speed up actual gene and drug discovery
The study was initiated by Simon Melov, director of genomics and one of the founding faculty members of the Buck Institute, and Mary Lopez, director of biochemistry at PerkinElmer Life and Analytical Sciences.
It involves the analysis of brain tissue samples from a unique study being conducted by researchers at the Rush Alzheimer's Disease Center.
The samples come from persons who have agreed to detailed annual clinical evaluations and brain donation at the time of death.
Further reading
Protein workstation details revealed
Claimed to be the first of its kind, this workstation fully automates the processing of microscope slide-based protein microarrays
More genes in human cDNA microarray
Human cDNA microarray system for researchers seeking access to premium gene content as well proprietary detection technology for ultra-sensitive gene expression results
Automated solution for protein purification
Collaboration has resulted in a 'breakthrough' platform for automating labour-intensive steps involved in protein purification
These tissue samples are exceptionally valuable for the kinds of studies being conducted by the Buck Institute and PerkinElmer because they are obtained from individuals from a known environment who have undergone extensive cognitive testing and detailed clinical history close to the time of death with a complete neuropathological profile.
The Buck Institute will conduct genomic studies on the tissue, and PerkinElmer will perform proteomic studies to identify differentially expressed proteins in Alzheimer's and normal human brain tissue.
PerkinElmer and the Buck Institute anticipate releasing their findings in a paper to be submitted later this year.
"Comprising both gene-expression and proteomic profiling, this large-scale collaboration will undoubtedly lead to important discoveries about gene and protein expression changes in relation to Alzheimer's disease," said Melov.
"PerkinElmer's advanced technology and intellectual capacity in proteomics, coupled with our extensive understanding of Alzheimer's disease, will accelerate the identification of disease-specific markers." According to the Alzheimer's Association, approximately four million Americans suffer from Alzheimer's disease.
Unless a cure or prevention is found, more than 14 million Americans will have Alzheimer's disease by the middle of the 21st century.
"Proteomic analysis of these valuable and clinically well-documented tissue samples will allow us to identify the proteins that are associated with changes in the brain for Alzheimer's disease patients," said Peter Coggins, president of PerkinElmer Life and Analytical Sciences.
"This will speed the development of proteomic-specific technology tools for the study of important disease-related changes." This proteomic analysis is taking place in PerkinElmer's Boston facility, and involves up to 30 scientists dedicating time to this research.
The human genome project gave us the ability to understand and know the 'human blueprint' through applications such as DNA sequencing.
Researchers now want to understand the assembly and function using the biological blueprint.
This information is contained in the structure, location and function of proteins.
Proteomics is the study of proteins and their dynamics and helps researchers to obtain the next level of understanding in their drug discovery process.
The analysis of the proteome requires separation, quantification, and identification of the full complement of proteins.
Identification is most commonly performed by separating proteins from a mixture utilising prefractionation, 2D-gel electrophoresis, excision of the desired protein spot from the gel and digestion of that protein into peptides.
These peptides, characteristic of any given protein, can be identified by using Maldi O-Tof mass spectrometry.
Analysts expect every pharmaceutical company and biotech company will be conducting proteomics research either in-house or through collaborations with other companies or research institutes.
• Perkin Elmer LAS (UK): contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
